12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARRY-520: Interim Phase Ib data

Interim data from 6 patients with relapsed or refractory MM who are refractory or intolerant to bortezomib in an investigator-sponsored, open-label, dose-escalation, U.S. Phase Ib trial showed no dose-limiting toxicities (DLTs) in the first cohort of patients receiving 0.75 mg/m 2 IV ARRY-520 plus 20/27 mg/m 2 carfilzomib. ARRY-520 was administered on days 1, 2, 15 and 16 of a 28-day cycle, while carfilzomib was administered on days 1, 2, 8, 9, 15 and 16. Patients received...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >